Adjuvant Low Dose Aspirin in Colorectal Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
ALASCCA is a randomized, parallel group, double blind, multicenter, placebo-controlled, biomarker-based study of adjuvant treatment with low dose aspirin in patients with colorectal cancer. Hypothesis is that patients diagnosed with colorectal cancer and somatic mutations in PI3K pathway can significantly improve survival if treated with low dose aspirin.
Epistemonikos ID: 20a7c4a9c4b3100ca116c09b593857138e49c6f7
First added on: May 12, 2024